Effects of atorvastain on tissue factor and tumor necrosis factor-alpha synthesis in peripheral blood monocytes from patients with acute coronary syndrome

Abstract

Abstract: AIM: To explore the effects of atorvastatin on the expression of tissue factor and TNF-α, and the tissue factor activity in peripheral blood monocytes from patients with acute coronary syndrome.METHODS: Monocytes were isolated from patients with acute coronary syndrome and cultured with atorvastatin (0, 0.1, 1, 10 μmol/L) for up to 24 hours.The tissue factor and tumor necrosis factor-alpha antigens in culture medium and cells were measured by enzyme-linked immunosorbent assay.The tissue factor activity was examined by chromogenic substrate assay and the mRNA levels were assessed by reverse-transcriptase polymerase chain reaction.RESULTS: Atorvastatin (0, 0.1, 1, 10μmol/L) dose-dependently decreased the levels of tissue factor [(5.8±1.3), (4.6±0.8), (3.7±0.9) and (2.7±0.5) ng/L, respectively] (P<0.05), and the activity of tissue factor [(16.2±3.2), (7.7±2.8), (4.3±0.8) and (3.8±0.8) pmol/L] (P<0.01) in peripheral blood monocytes from patients with acute coronary syndrome.These alterations were accompanied by a reduction in the levels of TNF-α[(306±40), (264±54), (229±24) and (189±44) ng/L, respectively] (P<0.05 ).CONCLUSION: The findings showed that atorvastatin reduced the tissue factor, TNF-αsynthesis and tissue factor activity in peripheral blood monocytes from patients with acute coronary syndrome, and thus potentially had the preventive and therapeutic effects on acute coronary syndrome.

Key words: acute coronary syndrome, tissue factor, tumour necrosis factor-alpha, atorvastatin

CLC Number:

R541

WU Xu-bin, TANG Sheng-xin, WU Guang-wei, LIN Ying-zhong, HU Chang-xin. Effects of atorvastain on tissue factor and tumor necrosis factor-alpha synthesis in peripheral blood monocytes from patients with acute coronary syndrome[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(1): 98-102.

References

[1] Gronholdt ML, Dalager-Pedersen S, Falk E.Coronary atherosclerosis: determinants of plaque rupture[J]. Eur Heart J, 1998, 19(Suppl C):C24-29.
[2] Moreno PR, Lodder RA, Purushothaman KR, et al. Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy[J]. Circulation, 2002, 105(8):923-927.
[3] Maseri A, Fuster V.Is there a vulnerable plaque[J] ?Circulation, 2003, 107(16):2068-2071.
[4] Braunwald E, Antman EM, Beasley JW, et al. ACC AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002:summary article:a report of the American College of Cardiology American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2002, 106(14):1893-1900.
[5] Grip O, Janciauskiene S, Lindgren S.Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes[J]. Inflamm Res, 2002, 51(2):58-62.
[6] Nagata K, Ishibashi T, Sakamoto T, et al. Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes[J]. J Hypertens, 2001, 19(4):775-783.
[7] Shah PK.Mechanisms of plaque vulnerability and rupture[J]. J Am Coll Cardiol, 2003, 41(4 Suppl S):15S-22S.
[8] Lutgens E, van Suylen RJ, Faber BC, et al. Atherosclerotic plaque rupture:local or systemic process l[J] ?Arterioscler Thromb Vasc Bio, 2003, 23(12):2123-2130.
[9] Corsini A, Ferri N, Cortellaro M.Are pleiotropic effects of statins real[J] ? Vasc Health Risk Manag, 2007, 3(5):611-613.
[10] Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial[J]. J Am Coll Cardiol, 2007, 49(12):1272-1278.
[11] Grip O, Janciauskiene S, Lindgren S.Pravastatin downregulates inflammatory mediators in human monocytes in vitro[J]. Eur J Pharmacol, 2000, 410(1):83-92.
[12] Ferro D, Parrotto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia[J]. J Am Coll Cardiol,2000, 36(2):427-431.
[13] Cortellaro M, Cofrancesco E, Arbustini E, et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque:the ATROCAP study[J]. Thromb Haemost,2002, 88(1):41-47.

[1]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[2]	PANG Shengfeng, ZHANG Jing, WU Ningning, LI Ru, CAO Jun, HE Shenghu. Efficacy of antiplatelet therapy with ticagrelor monotherapy after short-term double antibody therapy in patients with acute coronary syndrome after PCI [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1004-1009.
[3]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
[4]	DENG Yifan, HE Shenghu, WANG Daxin, DAI Chengye, XU Xiaoting, ZHANG Jing. Clinical study of effect of ezetimibe combined with statins on residual lipoprotein cholesterol and MACE events in patients undergoing emergency intervention with acute coronary syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1048-1052.
[5]	XIE Xiangmei, HUANG Zhihong, LIU Xiaoju, XUE Bing, LAN Baozhu. Effects of atorvastatin and folic acid tablets on homocysteine and carotid atherosclerosis in patients with type H hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 455-459.
[6]	LIU Hongdan, YIN Yihong. Qilin pills prevent ovarian hyperstimulation syndrome of patients after IVF-ET by regulating plasma-related indicators [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 196-202.
[7]	ZHANG Qian, FU Hong, CHEN Jinjin, ZHU Yubing. Research progress of IL33/ST2 in acute coronary syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1075-1080.
[8]	HUANG Lijia, HUANG Yang, KONG Jinsong, ZHENG Xin, GONG Xiaokang, RUAN Jianwei, WANG Haibao. Inhibition of articular cartilage degeneration by atorvastatin calcium via STAT1-caspase-3 signaling axis in rats with knee osteoarthritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 743-748.
[9]	YANG Yanan, CHEN Limei, TAO Chunlei. Bioequivalence study of atorvastatin calcium tablets in Chinese healthy volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1258-1264.
[10]	JIANG Hai, JIANG Guozhi, CHEN Zhong, LI Zhenjiang. Lipid-lowering effects of combined use of curcuma longa L.extracts and atorvastatin calcium in hyperlipidemia mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 48-51.
[11]	LU Yong-juan, CHEN Zhi-yun, YAN Mao-xiang, HE Bei-hui, ZHU Dan. Effect of atorvastatin on adipokines in rats with nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 520-524.
[12]	WU Ji-chu, OUYANG Ze-wei, LUO Can-xiang. Effect of ABCG2 genetic polymorphism on atorvastatin modifying serum lipids [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 882-884.
[13]	ZHANG Xia, KE Yong-sheng. Clinical research of new type P2Y12 Receptor inhibitor ticagrelor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(4): 459-464.
[14]	ZHENG Jian-lei, CHEN Qiu-jing, LU Lin, ZHANG Qi, ZHANG Rui-yan, SHEN Wei-feng. Atorvastatin ameliorates aortic YKL-40 level in diabetic rats fed with an atherogenic diet [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 133-138.
[15]	ZHOU Bi-rong, CHEN Yue-feng, ZHOU Na, YANG Jing. Changes of hs-CRP, CatS level in acute coronary syndrome patients serum and clinical significance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 1036-1039.